The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
|Articles|July 23, 2020
Episode 61: Preparing for Virtual High-Stakes Meetings
Author(s)Elaine Quilici
Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.
Advertisement
Jim and Cindy DiBiasi, co-founders of 3D Communications, discuss how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Pharmaceutical Executive Magazine
·
Episode 61: Preparing for Virtual High-Stakes Meetings
Advertisement
Related to this article
Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
Closing the Pediatric Evidence Gap
4
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
5